https://pharmadevicenews.com/annamycin-leukemia-trial-progresses-toward-pivotal-dose-selection-after-encouraging-interim-results/ PharmaDeviceNews en 2026-11-04T18:10:00+00:00 Annamycin leukemia trial progresses toward pivotal dose selection after encouraging interim results American Society of Hematology, annamycin, Arensia Exploratory Medicine, MIRACLE trial, Moleculin Biotech, naxtarubicin https://pharmadevicenews.com/wp-content/uploads/2026/11/Myeloid-leukemia-research-e1793815690864.webp https://pharmadevicenews.com/kairos-pharma-highlights-17-7-month-progression-free-survival-with-env-105-combination-in-metastatic-prostate-cancer/ PharmaDeviceNews en 2026-11-04T04:09:42+00:00 Kairos Pharma highlights 17.7-month progression-free survival with ENV-105 combination in metastatic prostate cancer Apalutamide, Cancer R&D 2026, Carotuximab, Cedars-Sinai Medical Center, City of Hope, ENV-105, enzalutamide, Houston, Huntsman Cancer Institute, John Yu, Kairos Pharma, Neil Bhowmick, United Scientific Group https://pharmadevicenews.com/wp-content/uploads/2026/10/Prostate-cancer-research-e1793137215571.webp https://pharmadevicenews.com/bayers-asundexian-cut-recurrent-stroke-risk-by-26-but-can-new-aha-evidence-strengthen-its-global-approval-prospects/ PharmaDeviceNews en 2026-11-04T04:05:56+00:00 Bayer’s asundexian cut recurrent stroke risk by 26%, but can new AHA evidence strengthen its global approval prospects? American Heart Association, asundexian, Bayer AG, Chicago, CONFIDENCE, Empagliflozin, FINE-HEART, FINEARTS-HF, Finerenone, Kerendia, OCEANIC-STROKE, Sunharbo https://pharmadevicenews.com/wp-content/uploads/2026/05/Coredio-advances-wearable-based-heart-failure-assessment-with-FDA-breakthrough-designation-e1780030409276.webp https://pharmadevicenews.com/imperative-care-reports-comparable-30-day-outcomes-for-women-and-men-in-106-patient-pulmonary-embolism-analysis/ PharmaDeviceNews en 2026-11-04T03:54:21+00:00 Imperative Care reports comparable 30-day outcomes for women and men in 106-patient pulmonary embolism analysis Arman Qamar, Aymen Ahmed, Endeavor Health, Imperative Care, San Diego, Society for Cardiovascular Angiography and Interventions, Symphony Thrombectomy System, SYMPHONY-PE https://pharmadevicenews.com/wp-content/uploads/2026/06/Imperative-Cares-Symphony-data-point-to-an-earlier-treatment-advantage-without-proving-a-golden-hour-e1781840645711.webp https://pharmadevicenews.com/evx-01-personalized-cancer-vaccine-moves-into-focus-as-evaxion-examines-broader-immune-responses/ PharmaDeviceNews en 2026-11-04T00:52:32+00:00 EVX-01 personalized cancer vaccine moves into focus as Evaxion examines broader immune responses Evaxion, EVX-01, Keytruda, Merck & Co., Society for Immunotherapy of Cancer https://pharmadevicenews.com/wp-content/uploads/2026/11/Cancer-vaccine-research-e1793753282441.webp https://pharmadevicenews.com/pas-004-advances-toward-phase-2-as-pasithea-seeks-new-treatment-approach-for-cutaneous-neurofibromas/ PharmaDeviceNews en 2026-11-03T23:39:48+00:00 PAS-004 advances toward Phase 2 as Pasithea seeks new treatment approach for cutaneous neurofibromas European Neurofibromatosis Conference, neurofibromatosis type 1, PAS-004, Pasithea Therapeutics, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/11/Skin-tumor-examination-e1793749024278.webp https://pharmadevicenews.com/t-cypher-bio-reports-promising-cancer-cell-killing-with-two-next-generation-t-cell-engagers/ PharmaDeviceNews en 2026-11-03T23:24:46+00:00 T-Cypher Bio reports promising cancer cell killing with two next-generation T-cell engagers. LifeArc Ventures, Medicxi, Oxford Science Enterprises, Society for Immunotherapy of Cancer, T-Cypher Bio, TC11, TC25 https://pharmadevicenews.com/wp-content/uploads/2026/11/Cancer-immunotherapy-research-e1793747959354.webp https://pharmadevicenews.com/trastuzumab-pamirtecan-slows-breast-cancer-progression-but-raises-interstitial-lung-disease-concerns/ PharmaDeviceNews en 2026-11-03T23:03:00+00:00 Trastuzumab pamirtecan slows breast cancer progression but raises interstitial lung disease concerns AstraZeneca, BioNTech, Daiichi Sankyo, Duality Biologics, DYNASTY-Breast02, trastuzumab pamirtecan, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/11/Breast-cancer-treatment-e1793746728306.webp https://pharmadevicenews.com/guardian-pharmacy-services-has-made-another-tennessee-acquisition-but-can-its-local-first-model-sustain-national-growth/ PharmaDeviceNews en 2026-11-03T07:09:31+00:00 Guardian Pharmacy Services has made another Tennessee acquisition, but can its local-first model sustain national growth? David Brown, Emily Haskins, Guardian Pharmacy Services Inc., Martin, Mike Swaim, Nautilus Pharmacy, Tennessee, Van's Institutional Pharmacy, Wellness Concepts, Zach Delaney https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/aarvik-therapeutics-advances-arr-002-into-phase-1-and-licenses-two-adc-candidates-to-laurus-labs-for-india/ PharmaDeviceNews en 2026-11-03T07:06:25+00:00 Aarvik Therapeutics advances ARR-002 into Phase 1 and licenses two ADC candidates to Laurus Labs for India Aarvik Therapeutics, AQUALINK, ARR-002, ArriVent BioPharma, AV-P138-ADC, Jagath Reddy Junutula, Laurus Labs Limited, MUTTA, San Diego, Satyanarayana Chava, Shanghai Allist Pharmaceuticals https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/blackstone-and-boston-scientific-strike-455m-vitalyst-deal-targeting-cardiogenic-shock-treatment-by-2030/ PharmaDeviceNews en 2026-11-03T07:03:02+00:00 Blackstone and Boston Scientific strike $455m VITALYST deal targeting cardiogenic shock treatment by 2030 Abiomed, Blackstone Inc., Blackstone Life Sciences, Boston Scientific Corporation, DanGer Shock, Impella, Johnson & Johnson, Mike Mahoney, Nicholas Galakatos, VITALYST https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/mirum-pharmaceuticals-prepares-new-brelovitug-volixibat-and-livmarli-data-for-aasld-2026/ PharmaDeviceNews en 2026-11-03T04:08:24+00:00 Mirum Pharmaceuticals prepares new brelovitug, volixibat and LIVMARLI data for AASLD 2026 American Association for the Study of Liver Diseases, AZURE-1, brelovitug, Chris Peetz, Denver, EXPAND, LIVMARLI, maralixibat, Mirum Pharmaceuticals Inc., VISTAS, Volixibat https://pharmadevicenews.com/wp-content/uploads/2026/11/Mirums-Rare-Liver-Disease-Breakthroughs-e1793678831865.webp https://pharmadevicenews.com/gileads-weekly-hiv-pill-has-passed-phase-3-but-can-fewer-doses-deliver-better-treatment-adherence/ PharmaDeviceNews en 2026-11-03T04:03:04+00:00 Gilead’s weekly HIV pill has passed Phase 3, but can fewer doses deliver better treatment adherence? ARTISTRY, BIKTARVY, Bixlenvo, Gilead Sciences Inc., HIV Glasgow, islatravir, ISLEND, Jared Baeten, Lenacapavir, Merck & Co., PURPOSE 5, Yeytuo, Yeztugo https://pharmadevicenews.com/wp-content/uploads/2026/11/Gilead-HIV-Glasgow-2026-Research-Briefing-e1793678515393.webp https://pharmadevicenews.com/heartbeam-3d-ecg-achieves-81-8-specificity-in-132-patient-heart-attack-study-beating-standard-ecg-on-one-measure/ PharmaDeviceNews en 2026-11-03T03:58:54+00:00 HeartBeam 3D ECG achieves 81.8% specificity in 132-patient heart attack study, beating standard ECG on one measure ALIGN-ACS, Belgrade, Branislav Vajdic, Graham Nichol, HeartBeam Inc., Serbia, Transcatheter Cardiovascular Therapeutics, United States Food and Drug Administration, University of Washington https://pharmadevicenews.com/wp-content/uploads/2026/11/HeartBeams-Promising-ACS-Pilot-Data-e1793678269289.webp https://pharmadevicenews.com/nasal-foralumab-reduces-brain-inflammation-marker-in-phase-2a-multiple-sclerosis-trial/ PharmaDeviceNews en 2026-11-03T02:32:44+00:00 Nasal foralumab reduces brain inflammation marker in Phase 2a multiple sclerosis trial Brigham and Women's Hospital, Foralumab, Harvard Medical School, INFORM-MS, Mass General Brigham, Tiziana Life Sciences https://pharmadevicenews.com/wp-content/uploads/2026/11/Multiple-sclerosis-research-e1793672821974.webp https://pharmadevicenews.com/huntingtons-disease-treatment-milestone-uniqure-secures-priority-fda-review-for-one-time-gene-therapy/ PharmaDeviceNews en 2026-11-02T20:05:07+00:00 Huntington’s disease treatment milestone: uniQure secures priority FDA review for one-time gene therapy AMT-130, Enroll-HD, Huntington's disease, ifezuntirgene inilparvovec, U.S. Food and Drug Administration, uniQure https://pharmadevicenews.com/wp-content/uploads/2026/11/Gene-therapy-research-e1793649589897.webp